TG Therapeutics (FRA:NKB2) Total Stockholders Equity : €173.1 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Total Stockholders Equity?

TG Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €173.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. TG Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was €1.11. The ratio of a company's debt over equity can be used to measure how leveraged this company is. TG Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 was 1.32.

TG Therapeutics Total Stockholders Equity Historical Data

The historical data trend for TG Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Total Stockholders Equity Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

34.75

426.91

209.88

55.31

147.18

TG Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															154.39	147.18	147.30	164.96	173.13

TG Therapeutics (FRA:NKB2) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

TG Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(173.133	-	0)	/	155.777
	=	1.11

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

TG Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.109	+	227.572)	/	173.133
	=	1.32

TG Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

TGTX:USA 0VGI:UK

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics Headlines

No Headlines